FOXA1 expression in non-small cell lung cancer and its correlation with metastasis

doi:10.3877/cma.j.issn.2095-5820.2021.03.005

Abstract

Abstract:

Objective

To investigate the expression of FOXA1 in primary and metastatic non-small cell lung cancer (NSCLC) and its correlation with metastasis.

Methods

Patients with pathologically confirmed NSCLC from The Affiliated Cancer Hospital & Institute of Guangzhou Medical University from September 2011 to December 2016 were randomly collected, including mismatched tissue samples from 40 primary lesions and 40 metastatic lesions, and tissue samples from 40 stage Ⅰ and 40 stage Ⅳ patients. The expression of FOXA1 was detected by immunohistochemistry and the difference in different tissues was compared. The expression of FOXA1 in 12 cases of stage Ⅳ non-small cell lung cancer with both primary and metastatic tissues was analyzed.

Results

FOXA1 was mainly expressed in the nucleus, but not in the cytoplasm and membrane. In 40 pairs of lung cancer tissues and metastatic tissues, the expression level of FOXA1 in metastatic tissues was significantly higher than that in lung cancer tissues (P＜0.05). The expression level of FOXA1 in stage Ⅳ lung cancer tissue was significantly higher than that in stage Ⅰ lung cancer tissue (P＜0.05). The expression level of FOXA1 in primary and metastatic foci of 12 patients with NSCLC was different. The expression level of FOXA1 in metastatic foci was higher than that in primary foci, but the P value was not statistically significant.

Conclusion

FOXA1 may be related to the metastasis of NSCLC and is expected to become a new therapeutic target for NSCLC.

Key words: FOXA1, Non-small cell lung cancer, Immunohistochemistry, Metastasis

Xingyang Xue, Yongquan Lan, Dandan Ding, Huazhen Wu, Zhiming Luo, Jian Zhao. FOXA1 expression in non-small cell lung cancer and its correlation with metastasis[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2021, 09(03): 150-153.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2021.03.005

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2021/V09/I03/150

Figures/Tables 3

References 21

1	Bray F, Ferlay J, Soerjomataram I, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
2	Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3): 145-164.
3	Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments[J]. Lancet, 2017, 389(10066): 299-311.
4	Zhu T, Bao X, Chen M, et al. Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis[J]. Front Oncol, 2020, 10: 585284.
5	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
6	Brix DM, Bundgaard Clemmensen KK, Kallunki T. Zinc Finger Transcription Factor MZF1-A Specific Regulator of Cancer Invasion[J]. Cells, 2020, 9(1): 223.
7	Parolia A, Cieslik M, Chu SC, et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer[J]. Nature, 2019, 571(7765): 413-418.
8	Huang C, Liu J, Xiong B, et al. Expression and prognosis analyses of forkhead box A (FOXA) family in human lung cancer[J]. Gene, 2019, 685: 202-210.
9	Adams EJ, Karthaus WR, Hoover E, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes[J]. Nature, 2019, 571(7765): 408-412.
10	Cocce KJ, Jasper JS, Desautels TK, et al. The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer[J]. Cell reports, 2019, 29(4):889-903.e810.
11	Liu B, Qin J, Shen W, et al. FOXA1 promotes proliferation, migration and invasion by transcriptional activating KRT7 in human gastric cancer cells.[J] J Biol Regul Homeost Agents, 2019, 33(4):1041-1050.
12	Katoh M, Katoh M. Human FOX gene family (Review)[J]. Int J Oncol, 2004, 25(5):1495-500.
13	Nakshatri H, Badve S. FOXA1 in breast cancer[J]. Expert Rev Mol Med, 2009, 11:e8.
14	Cirillo LA, Lin FR, Cuesta I, et al. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4[J]. Mol Cell, 2002, 9(2): 279-89.
15	Watanabe H, Francis JM, Woo MS, et al. Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target[J]. Genes Dev, 2013, 27(2): 197–210.
16	Lin L, Miller CT, Contreras JI, et al. The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas[J]. Cancer Res, 2002, 62(18): 5273-5279.
17	Wang H, Meyer CA, Fei T, et al. A systematic approach identifies FOXA1 as a key factor in the loss of epithelial traits during the epithelial-to-mesenchymal transition in lung cancer[J]. BMC Genomics, 2013, 14: 680.
18	Deutsch L, Wrage M, Koops S, et al. Opposite roles of FOXA1 and NKX2-1 in lung cancer progression[J]. Genes Chromosomes Cancer, 2012, 51(6): 618-29.
19	Li J, Zhang S, Zhu L, et al. Role of transcription factor FOXA1 in nonsmall cell lung cancer[J]. Mol Med Rep, 2018, 17(1): 509-521.
20	Du H, Chen Y, Hou X, et al. PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC[J]. Cell Death Dis, 2017, 8(10): e3143.
21	Ye JJ, Cheng YL, Deng JJ, et al. LncRNA LINC00460 promotes tumor growth of human lung adenocarcinoma by targeting miR-302c-5p/FOXA1 axis[J]. Gene, 2019, 685: 76-84.

项目	FOXA1表达		χ²	P 值
项目	低	高	χ²	P 值
非匹配患者的肺癌组织	33	7	13.653	0.000
非匹配患者的转移灶组织	17	23

项目	FOXA1表达		χ²	P 值
项目	低	高	χ²	P 值
非匹配患者的肺癌组织	33	7	13.653	0.000
非匹配患者的转移灶组织	17	23

项目	FOXA1表达		χ²	P 值
项目	低	高	χ²	P 值
Ⅰ期肺癌组织	33	7	4.013	0.045
Ⅳ期肺癌组织	25	15

项目	FOXA1表达		χ²	P 值
项目	低	高	χ²	P 值
Ⅰ期肺癌组织	33	7	4.013	0.045
Ⅳ期肺癌组织	25	15

[1]	Guo Sun, Yingdong Xie, Chaoli Xu, Bin Yang. Clinical value of a nomogram based on ultrasonic and clinical features for predicting central and lateral cervical lymph node metastases of thyroid papillary carcinoma [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(07): 734-742.
[2]	Zhuangzhuang Wu, Xiaojuan Zhang, Zehong Shi, yao Shi, Shaoling Yuan. Prognostic value of ultrasound combined with mammography and PR and HER-2 status in high-grade and middle-low-grade ductal carcinoma in situ of the breast [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(06): 631-635.
[3]	Xia Kang, Hao Tian, Jin Qian, Yuan Gao, Hongming Miao, Xiaowei Qi. Osteorin attenuates osteolysis during bone metastasis of cancers through inhibiting osteoclastogenesis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 329-339.
[4]	Xu Tang, Bing Han, Wei Liu, Ruxing Chen. Analysis of risk factors for metachronous liver metastases after radical colorectal cancer surgery and construction of a predictive model [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 16-20.
[5]	Yutao Yuan, Jinlin Xing, Kefei Xie, Kai Yin. Correlation between CT findings and BRAF^V600E gene mutation and central lymph node metastasis in papillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 611-614.
[6]	Qingyan Yan, Xiaomei Yong, Hong Luo, Min Du. Prognostic factors and survival analysis of multicenter elderly patients with metastatic breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 636-638.
[7]	Cheng Xu, Lulu Wang, Shaohua Wang. Application of eluent thyroglobulin in metastatic lymph nodes of thyroid papillary carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 701-704.
[8]	Jian Chang, Feng Qiu, Yuqi Mao. Analysis of the relationship between ingestion inhibition factor-1 and liver metastasis after laparoscopic radical resection of colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 502-505.
[9]	Xiaoyan Wang, You Xiao, Ge Xiao, Zhenquan Wang. CT characteristics and risk factors of lung metastasis in elderly patients with colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 506-509.
[10]	Hongjie Yang, Zhichun Zhang, Yi Sun. Study progress in the diagnosis of lymph node metastasis of rectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 512-518.
[11]	Yicheng Huang, Chen Lu, Sizheng Sun, Chunzhao Yu. Expression of liver-specific transcription factors FOXA2 in human stepwise metastatic colorectal carcinoma model and its significance [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 396-403.
[12]	Qi Liu, Kai Zhang, Jiannan Li, Tongjun Liu. Current status and progress of biologic treatment for colorectal cancer liver metastases [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(05): 415-419.
[13]	Daijiang Liu, Junyan Jiang, Xiaoqiang Wan, Shaying Ma. Analysis of survival status and prognostic factors in patients with colorectal cancer with liver metastasis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 284-288.
[14]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[15]	Wenbo Niu, Fengpeng Wu, Yueping Liu, Chaoxi Zhou, Juan Zhang, Xuhua Hu, Baokun Li, Gueying Wang. Neoadjuvant chemoradiotherapy for treatment of locally advanced rectal cancer: Efficacy and tumor immune microenvironment changes [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 519-523.

Please choose a citation manager

Content to export